NEW YORK, NY / ACCESSWIRE / August 19, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
3M Company (MMM)
Investors Affected : February 9, 2017 - May 28, 2019
A class action has commenced on behalf of certain shareholders in 3M Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) 3M had vast internal evidence dating back decades confirming that polyfluoroalkyl substances (“PFAS”) are toxic (which was first publicly revealed in February 2018 by Minnesota’s Attorney General); (ii) 3M had a decades-long history of suppressing negative information and/or damaging data about PFAS; and (iii) 3M has legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS.
Shareholders may find more information at https://securitiesclasslaw.com/securities/3m-company-loss-submission-form/?id=3056&from=1
Karyopharm Therapeutics Inc (KPTI)
Investors Affected : on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.
A class action has commenced on behalf of certain shareholders in Karyopharm Therapeutics Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
Shareholders may find more information at https://securitiesclasslaw.com/securities/karyopharm-therapeutics-inc-loss-submission-form/?id=3056&from=1
Granite Construction Incorporated (GVA)
Investors Affected : October 26, 2018 - August 1, 2019
A class action has commenced on behalf of certain shareholders in Granite Construction Incorporated. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an “untenable” imbalance of risk sharing between the Company and the joint venture project owners; (3) as a result, the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/granite-construction-incorporated-loss-submission-form/?id=3056&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com: